CD88 Antibody (8D6): sc-53788
- CD88 Antibody (8D6) is a rat monoclonal IgG2a, cited in 4 publications, provided at 200 µg/ml
- raised against CD88 of human origin
- recommended for detection of CD88 of mouse, rat and human origin by WB, IP, IF and FCM
- available conjugated to either phycoerythrin or FITC for IF, IHC(P) and FCM
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for CD88 Antibody (8D6). This work is in progress.
QUICK LINKS
SEE ALSO...
CD88 Antibody (8D6) is a rat monoclonal IgG2a antibody that detects CD88 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and flow cytometry (FCM). CD88, also known as the C5a receptor (C5aR), is a G protein-coupled integral membrane protein that plays a crucial role in the immune response by serving as a receptor for the inflammatory peptide C5a. The interaction between C5a and CD88 is vital for mediating inflammatory processes, as C5a-CD88 binding triggers the activation of various immune cells, including neutrophils and macrophages, leading to the production of pro-inflammatory cytokines and acute phase proteins. CD88′s role is particularly important in conditions such as rheumatoid arthritis, where heightened CD88 expression has been linked to increased inflammation and tissue damage. CD88′s expression on various cell types, including epithelial and endothelial cells, underscores CD88′s significance in both innate and adaptive immunity, making anti-CD88 antibody (8D6) an essential tool for researchers studying inflammatory pathways and immune responses.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
CD88 Antibody (8D6) References:
- The C5a receptor is expressed in normal renal proximal tubular but not in normal pulmonary or hepatic epithelial cells. | Fayyazi, A., et al. 2000. Immunology. 99: 38-45. PMID: 10651939
- Role of C5a-C5aR interaction in sepsis. | Guo, RF., et al. 2004. Shock. 21: 1-7. PMID: 14676676
- Role of the C5a receptor (C5aR) in acute and chronic dextran sulfate-induced models of inflammatory bowel disease. | Johswich, K., et al. 2009. Inflamm Bowel Dis. 15: 1812-23. PMID: 19714742
- Influence of the C5a-C5a receptor system on breast cancer progression and patient prognosis. | Imamura, T., et al. 2016. Breast Cancer. 23: 876-885. PMID: 26494574
- The Model Structures of the Complement Component 5a Receptor (C5aR) Bound to the Native and Engineered hC5a. | Sahoo, AR., et al. 2018. Sci Rep. 8: 2955. PMID: 29440703
- The Complement Receptors C3aR and C5aR Are a New Class of Immune Checkpoint Receptor in Cancer Immunotherapy. | Wang, Y., et al. 2019. Front Immunol. 10: 1574. PMID: 31379815
- Evaluation of the Safety and Efficacy of Avacopan, a C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine: Protocol for a Randomized, Double-Blind, Active-Controlled, Phase 3 Trial. | Merkel, PA., et al. 2020. JMIR Res Protoc. 9: e16664. PMID: 32088663
- The C5a/C5a receptor 1 axis controls tissue neovascularization through CXCL4 release from platelets. | Nording, H., et al. 2021. Nat Commun. 12: 3352. PMID: 34099640
- C5a receptor inhibitor avacopan in immunoglobulin A nephropathy-an open-label pilot study. | Bruchfeld, A., et al. 2022. Clin Kidney J. 15: 922-928. PMID: 35498891
- Avacopan, a Novel Competitive C5a Receptor Antagonist, for Severe Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis. | Nguyen, ID., et al. 2023. Clin Drug Investig. 43: 595-603. PMID: 37596445
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD88 Antibody (8D6) | sc-53788 | 200 µg/ml | $316.00 | |||
CD88 Antibody (8D6) FITC | sc-53788 FITC | 200 µg/ml | $330.00 | |||
CD88 Antibody (8D6) PE | sc-53788 PE | 200 µg/ml | $343.00 |